Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Harmony Biosciences Holdings (HRMY) Cost of Revenue: 2019-2025

Historic Cost of Revenue for Harmony Biosciences Holdings (HRMY) over the last 6 years, with Sep 2025 value amounting to $59.6 million.

  • Harmony Biosciences Holdings' Cost of Revenue rose 39.44% to $59.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $184.2 million, marking a year-over-year increase of 26.55%. This contributed to the annual value of $156.8 million for FY2024, which is 29.35% up from last year.
  • Harmony Biosciences Holdings' Cost of Revenue amounted to $59.6 million in Q3 2025, which was up 56.34% from $38.2 million recorded in Q2 2025.
  • In the past 5 years, Harmony Biosciences Holdings' Cost of Revenue ranged from a high of $59.6 million in Q3 2025 and a low of $15.5 million during Q1 2021.
  • In the last 3 years, Harmony Biosciences Holdings' Cost of Revenue had a median value of $32.3 million in 2023 and averaged $37.2 million.
  • Data for Harmony Biosciences Holdings' Cost of Revenue shows a peak YoY spiked of 70.76% (in 2023) over the last 5 years.
  • Harmony Biosciences Holdings' Cost of Revenue (Quarterly) stood at $19.1 million in 2021, then soared by 32.25% to $25.3 million in 2022, then skyrocketed by 70.76% to $43.2 million in 2023, then climbed by 26.09% to $54.4 million in 2024, then surged by 39.44% to $59.6 million in 2025.
  • Its Cost of Revenue stands at $59.6 million for Q3 2025, versus $38.2 million for Q2 2025 and $32.0 million for Q1 2025.